Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy - Wikidata - awgldk - TriplyDB

Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy

Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy

http://www.wikidata.org/entity/Q28383325

about

Maximizing the clinical utility of antimüllerian hormone testing in women's health Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review Comparability of antimüllerian hormone levels among commercially available immunoassays Self-collected dried blood spots as a tool for measuring ovarian reserve in young female cancer survivors The physiology and clinical utility of anti-Mullerian hormone in women.Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients Reduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromes Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide Chemotherapy: Impact on Anti-Müllerian Hormone Levels in Breast Carcinoma.Preserving Fertility in Children and Adolescents with Cancer.Fertility outcome of breast cancer and Hodgkin's lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists.Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.Infertility in reproductive-age female cancer survivors.Chemotherapy-induced damage to ovary: mechanisms and clinical impact.Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles.Best Practices in Counseling Young Female Cancer Survivors on Reproductive Health.Genetic variants of age at menopause are not related to timing of ovarian failure in breast cancer survivors.The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.Ovarian function after chemotherapy in young breast cancer survivors.Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis.Reproductive function assessment after surgery plus chemotherapy for germ cell ovarian tumors (MOGCT): novel clues deriving from the field of fertility preservation.

P2860

Q26822937-A014C786-F21A-4610-9F18-4267B00B7F62 Q28239980-CE9DD284-F1BC-4306-91AE-ED62B4A27C7D Q28384104-A46D369A-4646-4E8F-BC07-6114A09ED82D Q28388149-07C60DC0-6C20-4F80-8A19-7506767736D3 Q28396648-F02055E0-C4CC-4EBF-838D-FA789BA5FC0C Q34398233-D15319EC-0BA7-4C96-A4FD-EF85B3D52CC5 Q34550633-627C3912-52EB-429A-86C2-B27B8F583441 Q35055118-F80E0DA1-48DB-45A2-B383-BB2F51996375 Q35070210-737BDEDD-AA28-4568-84C8-4C3221678EE0 Q36370462-810CD418-94C7-402A-A141-F9A74004DD33 Q36708416-4FC42A98-4D60-4356-9AA9-758A3B20D02C Q37055811-EADD3C82-0348-44C3-B375-48EE1D27EAD3 Q38113299-8ED3EB97-04F2-4C02-A012-41E8FA8232B3 Q38250303-1BC48479-C113-4597-8F75-3A0859568980 Q38343285-40BCA7D8-1255-4FBD-A11C-172AB9D93620 Q38842887-C9529CE3-AFC4-490C-8E50-3EE99A24C386 Q40566569-02BA6E5F-A661-496F-BDFE-3E86632E2CDC Q46065513-DEC0F88D-168D-45F8-8B9A-0543131BBCB4 Q46104269-BF86E637-572C-44EC-A421-EC38BDF127C9 Q47097531-6CEE7EE6-CE43-4411-AAC9-F86D5A6449BF Q47124589-8A3FD5AA-5D0E-4645-ACD9-6E3725C145C5 Q47853555-DC33F634-B89D-437E-B99D-6BB92C47F658 Q48597947-36CDE8DB-AD80-4309-B4B0-29DBA60FE980

P2860

Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy

http://www.wikidata.org/entity/Q28383325

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Pretreatment antimüllerian hor ...... during and after chemotherapy

@ast

Pretreatment antimüllerian hor ...... during and after chemotherapy

@en

Pretreatment antimüllerian hor ...... during and after chemotherapy

@nl

type

label

Pretreatment antimüllerian hor ...... during and after chemotherapy

@ast

Pretreatment antimüllerian hor ...... during and after chemotherapy

@en

Pretreatment antimüllerian hor ...... during and after chemotherapy

@nl

prefLabel

Pretreatment antimüllerian hor ...... during and after chemotherapy

@ast

Pretreatment antimüllerian hor ...... during and after chemotherapy

@en

Pretreatment antimüllerian hor ...... during and after chemotherapy

@nl

P1433

Q28383325-E9280649-B795-4DCE-8D6B-CF7BFF21FE28

P1476

Q28383325-053210B3-A746-4386-A54E-49B933672157

P2093

Q28383325-1E5AABD7-F2F4-49A6-A860-680ACD3880E2

Q28383325-373ADE50-1C21-4560-A07E-E27C895071A6

Q28383325-511C3BA4-DF16-4198-8684-3D9396647939

Q28383325-824AF1ED-0B48-4AA0-8AE7-37043926B99B

Q28383325-88E29947-11DF-4C97-BF39-3A8142180B71

Q28383325-A7DF74AB-F504-48EF-B9C2-89A478B62930

Q28383325-B6364CD3-5567-4E72-9817-02E5D7D6E75C

Q28383325-CC20B49D-4B11-40A8-904E-89387DB9804F

P2860

Q28383325-0719330C-36CE-48A1-9F7D-CB5C42150582

Q28383325-18AB4E00-BFCC-4C6D-BD95-6095BE615F04

Q28383325-1CC2BBC7-78F4-40FD-88E1-182A3952117E

Q28383325-249891E6-EFF9-4FA6-A64A-23B778C63C7C

Q28383325-2B2028EC-88D7-4B9B-8DAA-1183FF9790B7

Q28383325-31840C77-3F8B-43C1-8F08-487A4D5C82EC

Q28383325-5115E580-4EA2-404B-8131-D72355BB1390

Q28383325-543BF147-D2EE-486B-A334-F293F8FECD12

Q28383325-650133E8-7957-4A01-ABF6-EEE9133E9ECD

Q28383325-6BA0CC45-6740-43AB-91BF-108603D7CD04

P304

Q28383325-C99CA807-800E-47AD-B6D3-6B2B5007BE8B

P31

Q28383325-98FD49EA-05A1-4594-8F2C-0CC09A40933C

P356

Q28383325-00F523C9-1EBF-47B9-9DC4-509B20C3B135

P407

Q28383325-56706129-4D2F-41F7-AE2C-F06F23D46881

P433

Q28383325-F914FB27-CE08-46D0-B1D5-91263181D1F1

P478

Q28383325-FA82470E-3178-4A6D-BD3A-EDF8E4972446

P577

Q28383325-D361F443-6EC5-4EA6-BAD2-C8DE48DDEA07

P5875

Q28383325-5D1F5EE8-6827-4691-9378-4B45AD025FEE

P698

Q28383325-62F2A7F1-9F59-40C3-A9C6-BB35D5F967E9

P921

Q28383325-35DFD3E4-CB42-4DDE-82EC-90E9EAD1DC0D

Q28383325-5BB4C555-5F87-4330-9E5F-CC949B7E9F69

P932

Q28383325-641559FA-05B3-4194-BD01-51081B46FA26

P356

J.FERTNSTERT.2012.09.039

P1433

Fertility and Sterility

P1476

Pretreatment antimüllerian hor ...... during and after chemotherapy

@en

P2093

Clarisa R Gracia

http://www.w3.org/2001/XMLSchema#string

Dana Walker

http://www.w3.org/2001/XMLSchema#string

Jennifer E Mersereau

http://www.w3.org/2001/XMLSchema#string

Jill P Ginsberg

http://www.w3.org/2001/XMLSchema#string

Katherine E Dillon

http://www.w3.org/2001/XMLSchema#string

Mary D Sammel

http://www.w3.org/2001/XMLSchema#string

Maureen Prewitt

http://www.w3.org/2001/XMLSchema#string

Yasmin Gosiengfiao

http://www.w3.org/2001/XMLSchema#string

P2860

Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years

Impact of cancer therapies on ovarian reserve

A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer

Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study.

Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.

Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer.

A characterization of the relationship of ovarian reserve markers with age

American Society of Clinical Oncology recommendations on fertility preservation in cancer patients.

Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count.

P304

477-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.FERTNSTERT.2012.09.039

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232529348

http://www.w3.org/2001/XMLSchema#string

P698

23084267

http://www.w3.org/2001/XMLSchema#string

P921

reproductive medicine

P932

3661215

http://www.w3.org/2001/XMLSchema#string